Search PubMed⌕ Search

Biomedical subjects

J B Moberly

Publications and source records attributed to J B Moberly.

23 records · Page 2Linked to original sources

Decreased activity of acyl-CoA:cholesterol acyltransferase by insulin in human intestinal cell line Caco-2.

Diabetes mellitus is accompanied by increased intestinal cholesterol synthesis and cholesterol esterification. Both are reversed by insulin therapy. To assess whether the action of insulin on cholesterol esterification by intestinal cells is direct or mediated by other effectors associated with diabetes, we investigated the effect of insulin on the activity of microsomal acyl-CoA:cholesterol acyltransferase (ACAT) and on the incorporation rate of [14C]oleic acid into cholesteryl oleate in the Caco-2 human intestinal cell line. Microsomal ACAT activity of cells that were incubated with insulin for 3 h at a concentration of 1, 10, and 100 microU/ml was decreased by 48, 58, and 74%, respectively, compared with cells cultured in insulinfree medium. This effect was evident as soon as 10 min after the addition of 10 microU/ml insulin. The inhibition by insulin was reversible. After incubation for 24 h, intracellular esterified-cholesterol content and the ratio of esterified to nonesterified cholesterol were significantly lower in the cells treated with insulin (100 microU/ml) than in those not treated with insulin (esterified cholesterol 48.6 +/- 2.0 vs. 74.2 +/- 4.3 nmol/mg protein, respectively, P less than .005; esterified to nonesterified ratio 0.280 +/- 0.008 vs. 0.359 +/- 0.059, respectively, P less than .05). Cells cultured on filters manifested physiologic polarity; greater than 90% of [14C]oleic acid-labeled cholesterol ester secreted by cells was secreted into the basolateral chambers. Incorporation of [14C]oleic acid into cholesteryl oleate over 24 h in the cells and in the medium of the basolateral chamber was suppressed by 100 microU/ml insulin by 23 and 40%, respectively. These findings indicate that insulin acts directly on the enterocytes to suppress intestinal cholesterol ester synthesis and secretion.

Cell Line↗

A monoclonal antibody that recognizes a basolateral membrane protein in A6 epithelial cells.

The A6 cell line is a model for tight epithelia and studies of epithelial polarity. Monoclonal antibodies (MAbs) were produced by immunization of mice with intact A6 cells and fusion of spleen cells to generate hybridomas. Hybridoma supernatants were screened by ELISA to select MAbs binding to the apical membrane of confluent A6 cells. Localization of MAb binding was examined by indirect immunofluorescence using cross sections of A6 monolayers grown on collagen coated filters. One MAb, designated 13F12, was positive by apical surface ELISA but localized specifically to the basolateral membrane of cross sections of A6 monolayers on filters. Immunofluorescence labeling of confluent A6 cells grown on glass cover slips revealed that MAb 13F12 does not bind to the apical membrane, but binds to basolateral determinants in the regions of domes, where it appears able to penetrate cellular junctions. Subconfluent A6 cells express the antigen all over the cell surface. Cells approaching confluency express the antigen on the apical membrane of some cells but not others, and as the cells reach confluency, the antigen disappears from the apical surface, and the cells become fully polarized. A6 cells at confluency on glass cover slips are equally polarized as cells grown on filters with respect to this antigen. The antigen has been identified by immunoprecipitation as a 22 kDa protein. High concentrations of MAb 13F12 did not inhibit cell plating, indicating that the antigenic site is not directly involved in cell adhesion to the substrate. MAb 13F12 should prove to be a useful tool to study many aspects of epithelial polarity, including the signals involved in sorting of proteins to specific membrane domains.

Antibodies, Monoclonal↗

Heterogeneity of expression of apical membrane determinants in A6 epithelial cells.

Expression of apical membrane antigens by A6 cells is heterogeneous. The A6 cell line is a model system for sodium transport and hormone action in "tight" epithelia. To create probes for the study of sodium transport and aldosterone action, we generated monoclonal antibodies (MoAbs) by immunization of BALB/c mice with intact A6 cells. MoAbs binding to apical membrane determinants were selected by an enzyme-linked immunoadsorbance assay (ELISA) against the apical surface of confluent A6 monolayers. Examination of ELISA-positive MoAbs by indirect immunofluorescence on confluent cells grown on glass cover slips revealed heterogeneity of apical expression: individual cells comprising the monolayer were fluorescently labeled to variable degrees and some cells were unlabeled. Expression of one antigen, recognized by MoAb I4C1, was heterogeneous in cells at low density as well as for confluent cells. Another antibody, 2B8, exhibited heterogeneity of labeling in confluent A6 monolayers, but no labeling of any cells at low density. This heterogeneity of antigen expression suggested that A6 cells are not a single cell type. However, cloned A6 cells established by limiting dilution were also labeled heterogeneously by both antibodies. Thus the heterogeneity observed is not due to genetic inhomogeneity between cells. Expression of the antigens on apical membranes of cells grown on Millipore filters was heterogeneous for the antigen recognized by 2B8, but essentially homogeneous for that recognized by I4C1, suggesting that the degree of differentiation of the cells plays a role in the heterogeneous expression of apical antigens. This heterogeneity of expression of apical antigens adds new complexity to the study of A6 cells and the differentiation of epithelial cells in culture.

Animals↗

Peripheral-type benzodiazepine binding sites in a renal epithelial cell line (MDCK).

Madin-Darby canine kidney (MDCK) cells express a high density of binding sites (Bmax = 0.67 pmol/10(6) cells) for [3H]RO 5-4864, a peripheral-type benzodiazepine (BZD) receptor ligand. Receptor affinity (Kd = 45 nM) in MDCK cells is 30-50 fold lower than in rat kidney, but its pharmacological specificity is identical to that of peripheral-type BZD receptors in the rat kidney (PK 11195 greater than RO 5-4864 greater than diazepam = flunitrazepam greater than clonazepam). The MDCK cell line should provide a useful model system for studying the role of peripheral type BZD receptors in renal function.

Animals↗

Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia.

Apolipoprotein C-III (ApoC-III) plays an important role in the metabolism of triglyceride-rich lipoproteins and is known to be elevated in patients with uremia. To investigate the role of apoC-III in uremic dyslipidemia, we examined apoC-III, triglyceride levels and lipoprotein particles containing both apoB and apoC-III (LP-Bc) in 27 uremic patients prior to dialysis (predialysis), 30 patients on hemodialysis (HD) and 31 patients on peritoneal dialysis (PD). All three groups of patients had elevated levels of plasma apoC-III (20+/-7 mg/dl for predialysis, 18+/-5 for HD and 22+/-8 for PD, compared to 11+/-3 mg/dl for control subjects [p<0/01 for all comparisons]). ApoC-III was positively correlated with plasma triglycerides in PD patients (r = 0.86, p<0.0001), HD patients (r = 0.67, p<0.0001) and predialysis patients (r = 0.60, p<0.001) as well as in all patients combined (r = 0.75, p<0.0001). ApoC-III was also positively correlated with levels of LP-Bc in all three groups of patients, although this correlation was less strong (r = 0.46, p<0.0001 for all patients combined). In predialysis and PD patients, the majority of apoC-III was found in heparin precipitable lipoproteins, whereas the majority of apoC-III in HD patients was found in HDL, indicating less efficient lipolysis in predialysis and PD patients in comparison with HD. These data support the hypothesis that the elevation of apoC-III in uremia can alter the metabolism of triglyceride-rich lipoproteins, leading to an elevation in triglycerides and LP-Bc. Understanding the mechanism(s) of elevated apoC-III in uremia may help to clarify the causes of uremic dyslipidemia.

Adult↗